

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA HEALTH

China Health Technology Group Holding Company Limited

中國健康科技集團控股有限公司

*(Incorporated in the Cayman Islands with limited liability and formerly known as
China Bozza Development Holdings Limited 中國寶沙發展控股有限公司)*

(Stock code: 1069)

RESIGNATION OF EXECUTIVE DIRECTOR AND CHANGE OF CHIEF EXECUTIVE OFFICER

RESIGNATION OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of China Health Technology Group Holding Company Limited (the “**Company**”) hereby announces that Mr. Chan Wai Lung (“**Mr. Chan**”) has resigned as an executive Director with effect from 29 January 2024 due to his other business engagements requiring more of time.

Mr. Chan has confirmed that there is no disagreement with the Board and that he is not aware of any matters that need to be brought to the attention of the shareholders of the Company or the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in relation to his resignation. The Board takes this opportunity to express its sincere gratitude to Mr. Chan for his invaluable contributions to the Company in the past.

CHANGE OF CHIEF EXECUTIVE OFFICER

Following the resignation of Mr. Chan as an executive Director, the Board announces that Mr. Chan has resigned as the chief executive officer of the Company (the “**Chief Executive Officer**”) with effect from 29 January 2024.

Mr. Chan has confirmed that he has no disagreement with the Board and that he is not aware of any matters that need to be brought to the attention of the Shareholders or the Stock Exchange in relation to his resignation as the Chief Executive Officer. The Board would like to express its gratitude to Mr. Chan for his significant contribution during his term of office as the Chief Executive Officer.

The Board is pleased to announce that Mr. Wang Yibin (“**Mr. Wang**”) has been appointed as the Chief Executive Officer with effect from 29 January 2024.

The biography of Mr. Wang is as follows:

Mr. Wang, aged 55, was appointed as an independent non-executive Director on 30 June 2022 and was re-designated as an executive Director on 19 May 2023. Mr. Wang has more than 19 years of experiences in banking, insurance, fund investment and securities management. He had worked as a chief executive officer and a general manager of Bensun Plastic Metal Products Co., Ltd (博羅縣立泰塑膠五金製品有限公司) for more than 10 years. Mr. Wang obtained a bachelor’s degree in Business Administration from Henan University of Economics and Law in 1994.

Save as disclosed above, as at the date of this announcement, Mr. Wang (i) does not hold any other position with the Company or other members of the Group; (ii) does not have any relationship with the Directors, senior management, substantial or controlling shareholders (as defined in the Listing Rules) of the Company; (iii) has not held any directorship in any other public companies in the last three years, the securities of which are listed on any securities market in Hong Kong or overseas; and (iv) does not have any interests in the shares, underlying shares and debentures of the Company which are required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Mr. Wang has entered into a contract of appointment as an executive Director with the Company for a term of one year with effect from 19 May 2023, subject to retirement and re-election at general meetings pursuant to the articles of association of the Company. As at the date of this announcement, the Company and Mr. Wang has entered into a supplemental contract of appointment to supplement certain information including but not limited to the appointment of Mr. Wang as the Chief Executive Officer. Mr. Wang is entitled to receive a total annual remuneration of HK\$240,000 for his roles as an executive Director and the Chief Executive Officer. The remuneration is recommended by the remuneration committee of the Company with reference to the remuneration policy of the Company, his duties and the prevailing market level of remuneration for executives of similar positions.

Save as disclosed above, there is no other information which is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Mr. Wang as the Chief Executive Officer that need to be brought to the attention of the Shareholders and the Stock Exchange in relation to his appointment.

By order of the Board
China Health Technology Group Holding Company Limited
Professor Fei Phillip
Chairman and Executive Director

Hong Kong, 29 January 2024

As at the date of this announcement, the Board comprises Professor Fei Phillip and Mr. Wang Yibin as the executive Directors and Mr. Guo Zhonglong, Mr. Chau Wing Nam and Ms. Bu Xue as the independent non-executive Directors.

* *For identification purpose only*